Compare Novavax Inc (NVAX) vs Verisign, Inc. (VRSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Verisign, Inc. — how do they compare? Novavax Inc trades at $12.75 (market cap $1.82B), while Verisign, Inc. trades at $303.74 (market cap $26.92B). The key difference: Verisign, Inc. is far larger — about 14.8× Novavax Inc's market cap, and Verisign, Inc. pays a 1.09% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and Verisign, Inc. for 123 Days on average.
| NVAX | VRSN | |
|---|---|---|
Market Cap | $1.82B | $26.92B |
Volume | 6,198,505 | 1,921,402 |
Sector | Health | Technology |
52-Week High | $12.75 | $310.00 |
52-Week Low | $6.22 | $211.49 |
Typical Hold Time | 59 Days | 123 Days |
Enterprise Value | $1.39B | $28.23B |
Dividend Yield | — | 1.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $11.01, down 1.87% on the day, with a bullish technical signal from moving averages and strong analyst support (73.9% buy ratings). The company reported revenue of $1.12B in 2025 with a net income of $440.3M, marking a significant turnaround from prior losses, though 2026 projections show a return to negative net income. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivots toward its Matrix-M adjuvant platform through partnerships.
The outlook is mixed: strong valuation ratios (P/E of 3.14, EV/EBITDA of 1.72) and recent earnings beats suggest undervaluation, but persistent cash burn and negative equity pose risks. Investment opportunity lies in partnership-driven growth, while risks include execution challenges and reliance on vaccine demand. Wall Street sentiment remains optimistic despite fundamental volatility.
VeriSign (VRSN) trades at $297.79, up 1.21% today, with a bullish technical signal and strong fundamentals including a 49.77% net income margin. Recent earnings show mixed quarterly beats, while institutional buying and a pending Q3 2026 report highlight investor interest. The stock faces resistance near $299, with support at $296.
Outlook remains positive with a consensus price target of $348, driven by robust cash flow and domain growth, though risks include an antitrust lawsuit and high valuation multiples. The buy-rated stock offers upside potential but requires monitoring of legal and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Verisign, Inc.
Verisign is the sole authorized registry for several generic top-level domains, including the widely utilized .com and .net top-level domains. The company operates critical Internet infrastructure to support the domain name system, including operating two of the world's 13 root servers that are used to route Internet traffic. In 2018, the firm sold off its Security Services business, signalling a renewed focus on the core registry business.
Read more on VRSN →
